Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Turk J Gastroenterol ; 34(7): 753-759, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-37326153

RESUMO

BACKGROUND/AIMS: The aim of this study is to evaluate the parameters that might be associated with pathologically diagnosed microvascular invasion and poor differentiation, using complete blood count and routine clinical biochemistry test results, in hepatocellular carcinoma patients before liver transplantation. MATERIALS AND METHODS: The data of patients who underwent liver transplantation for hepatocellular carcinoma at our institute, between March 2006 and November 2021, was researched retrospectively. RESULTS: The incidence of microvascular invasion was 28.6%, poor differentiation rate was 9.3%, hepatocellular carcinoma recurrence rate after liver transplantation was 12.1%, and median time to recurrence was 13 months, in the patients with normal alpha-fetoprotein levels. After univariate and multivariate analysis, maximum tumor diameter >4.5 cm and the number of nodules (n > 5) were found to be independent risk factors for microvascular invasion, and number of nodules >4 and mean platelet volume ≤8.6 fL were found to be independent risk factors for poor differentiation. Serum alpha-fetoprotein levels were still within the normal range at the recurrence time, in 53% of the patients who had recurrence after liver transplantation, but surprisingly were elevated in 47% of the patients at time of hepatocellular carcinoma recurrence. CONCLUSIONS: In hepatocellular carcinoma patients with normal alpha-fetoprotein levels before liver transplantation, independent risk factors of the presence of microvascular invasion were maximum tumor diameter and number of nodules, and independent risk factors of poor differentiation were mean platelet volume and number of nodules. Furthermore, serum alpha-fetoprotein levels were still normal at time of recurrence in 53% of hepatocellular carcinoma patients whose alpha-fetoprotein levels were normal before liver transplantation but were elevated in 47% of the patients at recurrence time, despite having normal levels before liver transplantation.


Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Transplante de Fígado , alfa-Fetoproteínas , Humanos , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/patologia , alfa-Fetoproteínas/análise , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/patologia , Recidiva Local de Neoplasia , Masculino , Feminino , Criança , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso
3.
Exp Clin Transplant ; 2019 May 09.
Artigo em Inglês | MEDLINE | ID: mdl-31070565

RESUMO

OBJECTIVES: In irreversible acute liver failure, liver transplant is the only viable treatment option. In this study, our aim was to evaluate and determine the factors related to mortality in patients who received liver transplants in accordance with King's College criteria for acute liver failure in order to prevent futile operations. MATERIALS AND METHODS: Our study included 65 adult patients with acute liver failure who received liver transplant according to King's College criteria. Factors related to mortality, including demographic and operative data, causes of acute liver failure, severity of encephalopathy, and laboratory data, were retrospectively analyzed. Patients who received living-donor liver grafts had donations from first-degree to fourth-degree relatives. RESULTS: Of 65 patients analyzed, 55.3% were women. Ninety-day mortality rate was 36.9%. Preoperative bilirubin levels in survivor and nonsurvivor groups were 16.3 ± 9.6 and 21.3 ± 10.7 mg/dL, respectively (P = .03). Mortality rates of patients with bilirubin above and below 9 mg/dL were 31.8% and 8.3%, respectively (P = .03). Of patients who died, 75% were women (significantly more women than men, P = .015). Patients who had deceased-donor liver transplants had a significantly higher mortality rate than those who had living-donor liver transplants (52% vs 27.5% ; P = .046). At 3 days posttransplant, bilirubin, creatinine, aspartate aminotransferase, phosphorus, sodium, and ammonia levels were significantly different between survivor and nonsurvivor groups (P < .05). CONCLUSIONS: We found living-donor liver transplant to be superior versus deceased-donor liver transplant with regard to development of acute liver failure. Reasons could include the long wait period for deceased donors and liver grafts coming from marginal donors. Bilirubin level and presence of grade 4 encephalopathy had predictive values for poor prognosis of patients.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA